ARTERIAL HYPERTENSION requiring i.v. vasodilator therapy occurred early after coronary artery bypass surgery in approximately two out of three patients in an earlier study from this institution.' Although nitroglycerin is often viewed predominantly as a venodilator, our clinical studies of i.v. nitroglycerin in patients with acute myocardial infarction clearly indicate that, at higher infusion rates, nitroglycerin is also a potent arterial dilator. Nitroglycerin reduced both left ventricular filling pressure and mean arterial pressure, while stroke volume remained constant or increased.2' s Lowering of peripheral vascular resistance was greatest in patients who had hemodynamic evidence of severe left ventricular failure.
SUMMARY The present study was designed to test the hypothesis that i.v. nitroglycerin is as effective as sodium nitroprusside for managing acute hypertension early after coronary artery bypass surgery. Seventeen patients received both nitroglycerin and nitroprusside in a randomized crossover protocol. Infusion rates were increased stepwise to lower mean arterial pressures comparably with each drug. In 14 of 17 patients, similar infusion rates of the two vasodilators resulted in equal lowering of both blood pressure and systemic vascular resistance. In the remaining three patients, very high infusion rates of nitroglycerin were required and achieved only 20-50% of nitroprusside's response in two of three. Hemodynamic responses to the two vasodilators were similar, except that nitroglycerin increased cardiac output more than nitroprusside did. In contrast, pulmonary gas exchange responses differed in that nitroglycerin improved intrapulmonary shunting, while nitroprusside worsened it. Similarly, nitroglycerin resulted in a significantly smaller increase in the alveolararterial oxygen gradient than did nitroprusside. These results suggest that in the majority of patients, i.v. nitroglycerin was as effective as nitroprusside in controlling acute hypertension after coronary artery bypass surgery. In addition, nitroglycerin appeared to have more favorable effects on pulmonary gas exchange. Because nitroglycerin has more beneficial effects on intercoronary collateral blood flow in the setting of regional ischemia, it may be preferable to nitroprusside in patients with ischemic heart disease.
ARTERIAL HYPERTENSION requiring i.v. vasodilator therapy occurred early after coronary artery bypass surgery in approximately two out of three patients in an earlier study from this institution.' Although nitroglycerin is often viewed predominantly as a venodilator, our clinical studies of i.v. nitroglycerin in patients with acute myocardial infarction clearly indicate that, at higher infusion rates, nitroglycerin is also a potent arterial dilator. Nitroglycerin reduced both left ventricular filling pressure and mean arterial pressure, while stroke volume remained constant or increased.2' s Lowering of peripheral vascular resistance was greatest in patients who had hemodynamic evidence of severe left ventricular failure.
In the present study, we used a randomized crossover protocol to determine whether i.v. nitroglycerin could be as effective as sodium nitroprusside in reducing arterial pressure in patients who were acutely hypertensive after coronary bypass. Previous Hemodynamic variables at the time hypertension developed were recorded in all 17 patients before the initiation of vasodilator therapy. These variables included heart rate, cardiac output, mean arterial pressure, pulmonary capillary wedge pressure (or pulmonary artery diastolic pressure) and mean pulmonary artery pressure, as well as cardiac index, stroke work index, systemic vascular resistance index, pulmonary vascular resistance index and stroke volume index. After control measurements were obtained, patients were randomly assigned to one of two experimental protocols, depending on the last digit of their medical history number ( fig. 1 Infusion of each drug was begun at 5-10 Ag/min and increased stepwise every 3-5 minutes until mean arterial pressure was lowered 10-33% (10-40 mm Hg), depending on the starting value. Then, the hemodynamic effects were allowed to stabilize from approximately 20 minutes and cardiac output was remeasured to define a hemodynamic profile for the first vasodilator drug. The first vasodilator was then discontinued and infusion of the second drug begun. As the vasodilating effects of the initial agent began to decrease, the infusion rate of the second agent was increased in a stepwise fashion in an attempt to maintain mean arterial pressure at the same level reached with the first drug. When a stable infusion rate of the second vasodilator had been obtained, the hemodynamic effects were again allowed to stabilize for 20 minutes and cardiac output was remeasured to obtain a hemodynamic profile for the second vasodilator drug. Because all patients had significant drainage from their mediastinal tubes during the study, volume in the form of whole blood was administered simultaneously to replace surgical blood loss.
In eight of the 17 patients, pulmonary and tissue gas exchange were assessed by temporarily switching to an inspired oxygen concentration (Fio2) of 100% for 10 minutes during the control and each subsequent intervention period. Arterial oxygen tension (Pao2), mixed venous oxygen tension (Pvo2), alveolar-arterial oxygen gradient (AaDo2), intrapulmonary shunting (Qs/Qt) and tissue oxygen use (MVo2) could thereby be measured or calculated during each of these periods. 7 All results are expressed as mean ± SD. Statistical analysis was by two-way analysis of variance-repeated measures test, and individual comparisons were made only when analysis of variance revealed significant (p < 0.05) differences.
Results
The mean infusion rate of sodium nitroprusside required in all 17 patients to obtain the desired lowering of mean arterial pressure was 95 ± 116 ,ug/min. The mean infusion rate of nitroglycerin required to obtain a comparable lowering of arterial pressure was 304 i 440 ug/min. Fourteen patients responded to nitroglycerin infusions of less than 300 ,ug/min (range Ag/min. This mean infusion rate of nitroglycerin was not significantly different from the average infusion rate of nitroprusside in these same patients. After initiation of vasodilator therapy, arterial pressure decreased rapidly from a mean of 115 ± 18 mm Hg to 90 ± 9 mm Hg with nitroprusside and 90 ± 10 mm Hg with nitroglycerin (both p < 0.001 vs control) ( fig. 2A) . Systemic vascular resistance index decreased from an initially elevated level of 44 ± 9 units to normal levels of 31 ± 10 units with nitroglycerin and 31 ± 7 units with nitroprusside (both p < 0.001 vs control). Cardiac output increased from a control level of 2.4 ± 0.5 1/min/M2 to 2.7 ± 0.7 1/min/M2 with nitroprusside and to 2.9 ± 0.9 1/min/M2 with i.v. nitroglycerin. Only the increase in cardiac output obtained with i.v. nitroglycerin was statistically significant (p < 0.025 vs control). The heart rate increased from 85 ± 14 beats/ min during control to 93 ± 18 beats/min during nitroprusside and 93 ± 20 beats/min during nitroglycerin (both p < 0.025 vs control).
Because volume expanders were administered simultaneously with the vasodilator therapy, the preload-lowering effect of both agents was largely L Control TNP :1 TNG counteracted ( fig. 2B ). Left ventricular filling pressure (pulmonary capillary wedge pressure or pulmonary artery diastolic pressure), which was 11 ± 4 mm Hg before vasodilator therapy, was 10 ± 4 mm Hg during nitroprusside and 9 ± 3 mm Hg during i.v. nitroglycerin (NS). The control stroke work index was 38 ± 10 g-m/m2 and did not change significantly with either drug (32 ± 7 g-m/m2 during nitroprusside and 35 ± 12 g-m/m2 during nitroglycerin). Stroke volume increased slightly with both vasodilators, from a control value of 54 ± 11 ml to 59 i 19 ml during nitroglycerin and 56 ± 12 ml during nitroprusside (NS).
The mean pulmonary artery pressure decreased from a control value of 17 ± 5 mm Hg to 15 i 5 mm Hg with nitroglycerin and 16 ± 6 mm Hg with nitroprusside (NS) (fig. 2B ). Control pulmonary vascular resistances were normal (< 4 units); consequently, small decreases in pulmonary vascular resistance index, from 2.8 ± 1.9 units to 2.2 ± 1.4 units during nitroglycerin and 2.4 ± 1.3 units during nitroprusside, were not expected to reach significance.
Nitroglycerin and nitroprusside had differential effects on pulmonary gas exchange ( fig. 3) in the diastolic pressure-volume relationship of the left ventricle or an increase in contractility secondary to a reduction in ischemia. If peripheral venodilation alone were the mechanism, then venous return and thereby cardiac output should have decreased. In subsequent clinical studies, i.v. nitroglycerin at higher infusion rates (mean 57 ,ug/min) was a potent arterial dilator with a variable effect on stroke volume that depended on the presence or absence of left ventricular failure.2 Patients without left ventricular failure had a decrease in stroke volume as if they were moving leftward down the same Starling curve. This might be expected to result from venodilation and the associated reduction in venous return. Patients with mild-to-moderate left ventricular failure maintained or increased their stroke volume despite a significant reduction in their filling pressures, appearing to move leftward along the same flattened Starling curve or to shift upward and to the left to a more favorable Starling curve. Thus, patients with the greatest elevations of left ventricular filling pressure and the lowest stroke work obtained, in addition to the beneficial antiischemic effects demonstrated in all hemodynamic subgroups, the optimal hemodynamic effects as well.
We recently found that the incidence of acute hypertension during the first 5 hours after coronary artery bypass surgery was 61% (131 of 215 patients).1 We investigated the possible roles of renin-angiotensin and catecholamines in the pathogensis of this syndrome. At peak hypertension, plasma catecholamine levels were highest and renin and angiotensin levels were low. Plasma catecholamine levels were comparably elevated in both hypertensive and nonhypertensive patients. The An increase in collateral blood flow became the dominant antiischemic effect when preload-and afterloadlowering effects of nitroglycerin were reversed by returning arterial pressure to control levels.
In conclusion, i.v. nitroglycerin and nitroprusside are effective for the management of acute hypertension after coronary artery surgery. Nitroglycerin and nitroprusside reduced arterial pressure and systemic vascular resistance equally in the majority of patients. Nitroglycerin appears to have more favorable effects on pulmonary gas exchange and intrapulmonary shunting, which may be important in managing postoperative patients with pulmonary hypertension or those with intrinsic lung disease and large intrapulmonary shunts. In view of the directionally opposite effects of nitroglycerin and nitroprusside on the severity of regional ischemia, nitroglycerin appears to be preferable for use in patients with ischemic heart disease.
